Gastro-Intestinal Screening (GIS)

The early detection of gastrointestinal (GI) cancers such as esophageal, gastric, and pancreatic malignancies is crucial due to the potential for misdiagnoses during standard endoscopic evaluations. These types of cancer are frequently identified at advanced stages, leading to poor patient outcomes and limited treatment options.

GIS is a real-time intra-endoscopic electrical diagnostic probe designed to differentiate high-risk excision-requiring lesions using modified endoscopic biopsy forceps as a non-invasive method. During the standard endoscopy process, the decision to take a sample for pathology diagnosis is often based on the skill and experience of the endoscopist. In some cases, this decision results in additional costs for the patient, and in other cases, the failure to take a sample can lead to cancer not being diagnosed in the early stages.

Advantages and superiority of the Gastro-Intestinal Screening

Evidence from studies indicates that this technique demonstrates a high level of sensitivity and specificity in identifying small polyps and lesions that might not be easily observable through standard endoscopy. Overall, the results of Gastro-Intestinal Screening indicate its potential in cancer screening and surveillance.

The Gastro-Intestinal Screening device has attracted considerable interest in the medical sector because of its impressive success in detecting cancer at an early stage. A collaboration between researchers in the US and international partners led to the development of the GIS device, which has transformed the approach taken by doctors in diagnosing and treating different forms of cancer. Through the use of advanced electrical endoscopy technology, this groundbreaking device enables the non-invasive and precise identification of early-stage masses within the body. Doctors can improve their diagnostic abilities and offer better care to patients by incorporating the GIS device into their practice.